The enhanced tumour growth following LIF administration is supported by other studies in both breast and pancreatic cancer, where LIF administration and ectopic expression was shown to promote tumour growth and tumour progression in-vitro [24, 28]. Here, LIF is linked to familial pancreatic carcinoma.